The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1591
February 10, 2020
View Complete Issue         Table of Contents 2019 
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
February 10, 2020 (Issue: 1591)
Icosapent ethyl (Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
Article code: 1591a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.